Abstract
One of the major challenges of RNA-based therapeutics is the method for delivery of RNA molecules. In a recent article (Nat Commun 9(1):2359), we described a novel delivery platform for RNA-based drugs using red blood cell extracellular vesicles which can efficiently deliver both small and large RNAs to solid and liquid tumours. Our RBCEVs platform features exceptional merits over conventional RNA delivery methods in biosafety, biocompatibility, efficiency, accessibility, and cost effectiveness.
| Original language | English |
|---|---|
| Pages (from-to) | 239-241 |
| Journal | Cell Stress |
| Volume | 2 |
| Issue number | 9 |
| Online published | 30 Aug 2018 |
| DOIs | |
| Publication status | Published - Sept 2018 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Research Keywords
- Cancer
- RNA
- therapeutics
- extracellular vesicles
- red blood cells
Publisher's Copyright Statement
- This full text is made available under CC-BY 4.0. https://creativecommons.org/licenses/by/4.0/
Fingerprint
Dive into the research topics of 'Red blood cell extracellular vesicles as robust carriers of RNA-based therapeutics'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver